Table 2.
The meta-analysis results and corresponding qualities of evidence (GRADE)
| One month after treatment | |||
| PRP | b1.80(-6.68,10.28)/m | b5.49(-1.36,12.34)/m | b4.50(-1.88,10.88)/m |
| a1.49(-0.94,3.92)/m | PRF | b3.69(-3.81,11.19)/m | b0.81(-3.14,4.77)/m |
| a-0.36(-2.31,1.60)/l | a-1.85(-3.83,0.13)/l | HA | b2.99(-2.78,8.76)/l |
| a*-2.89(-4.63,-1.15)/l | a*-1.04(-2.00,-0.09)/m | a1.74(-0.19,3.68)/m | PO |
| Three months after treatment | |||
| PRP | b-2.31(-8.69,4.06)/l | b4.38(-1.70,10.47)/m | b*8.31(4.81,11.82)/m |
| a1.38(-0.76,3.52)/m | PRF | b*6.69(2.11,11.28)/m | b1.62(-1.33,4.57)/m |
| a-0.47(-1.85,0.91)/l | a-1.85(-4.02,0.31)/l | HA | b1.38(-3.43,6.20)/l |
| a-0.88(-1.89,0.14)/m | a*-2.26(-4.14,-0.37)/m | a-0.40(-1.50,0.70)/m | PO |
| Six months after treatment | |||
| PRP | b*-11.01(-16.17,-5.86)/l | b-2.29(-4.85,0.27)/l | b0.11(-2.07,2.29)/l |
| a-0.17(-2.88,2.54)/m | PRF | b*8.72(3.64,13.80)/m | b*11.12(6.45,15.79)/m |
| a-0.79(-1.65,0.07)/m | a-0.62(-3.33,2.09)/m | HA | b*2.40(0.40,4.40)/m |
| a*-1.17(-1.82,-0.51)/m | a-1.00(-3.63,1.63)/m | a-0.38(-1.06,0.30)/m | PO |
PRP Platelet-rich plasma, PRF Platelet-rich fibrin, HA Hyaluronic acid, PO Placebo, H High-quality evidence, M Moderate-quality evidence, L Low-quality evidence, VL Very Low-quality evidence
Interventions: PRP, PRF, HA, PO
aVAS difference value around treatment
bMMO difference value around treatment *; blod: statistically significant